[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ovarian-cancer-metastatic-recurrent\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ovarian-cancer-metastatic-recurrent":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,95,121],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100619095","phase-2-trastzumab-deruxtecan-versus-soc-in-recurrent-ovarian-that-progressed-on-prior-parp-inhibitor-therapy-100619095",false,"NCT07340164","Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy","A Phase 2, Open-label, Multicenter, Randomized Study of Trastuzumab Deruxtecan Versus Investigator's Choice Chemotherapy in Recurrent Ovarian Cancer That Progressed on Prior PARP Inhibitor Therapy: TROY (APGOT-OV14)","TROY","Inclusion Criteria:\n\n* 1\\. Adults ≥18 years of age on the day of signing the Informed Consent Form. Follow local regulatory requirements if the legal age of consent for trial participation is \\>18 years old.\n\n  2\\. Patient has signed the Informed Consent (ICF) and is able to comply with protocol requirements.\n\n  3\\. Has HER2 expression per 2016 ASCO-CAP gastric cancer IHC scoring (3+\u002F2+\u002F1+) guidelines by local tests.\n\n  4\\. Availability of tumor tissue for translational research: A formalin-fixed paraffin-embedded (FFPE) tumorblock (preferred) or at least 20 slides (unstained, freshly cut, serial sections) must be submitted.\n\n  5\\. Histologically confirmed high grade serous or high grade endometrioid ovarian, primary peritoneal, and\u002For fallopian tube cancer that is recurrent.\n\n  6\\. Patient with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n\n  7\\. Radiologically confirmed\u002Fdocumented disease progression while on PARP inhibitor therapy in either first or second-line maintenance setting Note: Documentation of disease progression must be within 180 days of last PARPi dose taken. Surgical salvage intervention and\u002For focal ablative therapies are allowed.\n  1. Clinically benefited from PARPi maintenance prior to documented progression, as defined by at least 6 months of treatment duration with no progressive disease observed.\n  2. Progression on first-line maintenance PARP inhibitor: Participants are allowed maximum 1 additional line of platinum-based chemotherapy before study entry (note: treatment-free interval on platinum rechallenge must be \\> 6 months, with documented disease progression prior to study entry.\n  3. Progression on second-line maintenance PARP inhibitor: Participants are not allowed any additional systemic anticancer treatment before study entry.\n\n     8\\. Patient with measurable disease according RECIST 1.1 criteria. 9. LVEF ≥50% within 28 days before randomization. 10. Patient has adequate organ function, defined as follows:\n\n  a) Absolute neutrophil count ≥ 1,500 cells\u002FμL b) Platelets ≥ 100,000 cells\u002FμL c) Hemoglobin ≥ 9 g\u002FdL or ≥ 5.6 mmol\u002FL d) Serum creatinine ≤ 1.5× upper limit of normal (ULN) or calculated creatinine clearance ≥ 50mL\u002Fmin using the Cockcroft-Gault equation for patients with creatinine levels \\> 1.5× institutional ULN e) Total bilirubin ≤ 1.5× ULN (≤ 2.0 x ULN in patients with known Gilbert's syndrome) or direct bilirubin ≤ 1× ULN f) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5× ULN unless liver metastases are present, in which case they must be ≤ 5× ULN g) International normalized ratio or prothrombin time (PT) ≤1.5× ULN and activated partial thromboplastin time ≤1.5× ULN. Patients receiving anticoagulant therapy must have a PT or partial thromboplastin within the therapeutic range of intended use of anticoagulants.\n\n  11\\. Patient must have a negative serum pregnancy test within 72 hours of the first dose of study medication, unless they are of nonchildbearing potential. Nonchildbearing potential is defined as follows:\n  1. Patient is ≥ 45 years of age and has not had menses for \\> 1 year.\n  2. A follicle-stimulating hormone value in the postmenopausal range upon screening evaluation if amenorrhoeic for \\\u003C 2 years without a hysterectomy and oophorectomy.\n  3. Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation:\n* Documented hysterectomy or bilateral oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound, MRI, or CT scan.\n* Tubal ligation must be confirmed with medical records of the actual procedure.\n* Information must be captured appropriately within the site's source documents. 12. Patient of childbearing potential must agree to use a highly effective method of contraception with their partners starting from time of consent through 150 days after the last dose of study treatment. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient (Information must be captured appropriately within the site's source documents) 13. Has proteinuria \\\u003C2+. If proteinuria is ≥2+, 24-hour urine must demonstrate \\\u003C1 g of protein in 24 hours.\n\nExclusion Criteria:\n\n\\- 1. Primary platinum-refractory disease defined as disease progression during primary platinum-based chemotherapy or platinum-resistant disease defined as disease progression within 6 months of the last platinum administration in the second-line setting.\n\n2\\. History of additional malignancy within 3 years before the date of enrolment. Exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the Investigator, with concurrence of the Sponsor, is considered cured with minimal risk of recurrence within 3 years. 3. Patient has received prior anticancer therapy (chemotherapy, targeted therapies, hormonal therapy, radiotherapy) within 21 days or \\\u003C 5 times the half-life of the most recent therapy prior to Study Day 1, whichever is shorter.\n\nNote: The washout period for radiation therapy is as follows: ≥ 4 weeks for palliative stereotactic radiation to chest and ≥2 weeks palliative stereotactic radiation therapy to other anatomic areas.\n\n4\\. Patient has known uncontrolled central nervous system metastases, carcinomatosis meningitis, or both.\n\nNote: Patients with previously treated brain metastases may participate provided they are stable (without evidence of disease progression by imaging \\[using the identical imaging modality for each assessment, either MRI or CT scan\\] for at least 4 weeks prior to the first dose of study treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and have not been using steroids for at least 7 days prior to study treatment. Carcinomatous meningitis precludes a patient from study participation regardless of clinical stability. 5. Active and\u002For uncontrolled infection. The following exceptions apply:\n\n1. Participants with HIV infection are eligible if followings are met: a. CD4+ T-cell count ≥350 cells\u002Fmm3 at the time of screening, b. Virologic suppression defined as confirmed HIV RNA level below 50 or the LLOQ (below the limit of detection) at the time of screening and for at least 12 weeks before screening, c. No AIDS-defining opportunistic infections or conditions within the past 12 months, d. On stable ART regimen, without changes in drugs or dose modification, for at least 4 weeks before trial entry (Day 1) and agree to continue ART throughout the trial.\n2. Participants with evidence of chronic HBV infection are eligible if the followings are met: a. the HBV viral load is \\\u003C2000 IU\u002FmL b. start or maintain antiviral treatment, if clinically indicated as per the investigator. c. they have normal transaminase values, or, if liver metastases are present, abnormal transaminases with a result of AST\u002FALT \\\u003C3 × ULN, which are not attributable to HBV infection.\n3. Participants with a history of HCV infection are eligible if History of hepatitis C infection eligible if the HCV viral load is below the level of detection in the absence of antiviral therapy during the previous 4 weeks and if they Have normal transaminase values, or, if liver metastases are present, abnormal transaminases with a result of AST\u002FALT \\\u003C3 × ULN, which are not attributable to HCV infection.\n\n   6\\. Patient has not recovered (i.e., to Grade ≤ 1 or to baseline) from cytotoxic therapy-induced adverse events(AEs).\n\nNote: Patients with Grade ≤ 2 neuropathy, Grade ≤ 2 alopecia, or Grade ≤ 2 fatigue are an exception to this criterion and may qualify for the study.\n\n7\\. Patient has not recovered adequately from AEs or complications from any major surgery prior to starting therapy.\n\n8\\. Patient has a known hypersensitivity to the active substances or to any excipients of the study intervention 9. Evidence of active or ongoing bowel obstruction 10. Has a history of (non-infectious) interstitial lung disease (ILD)\u002Fpneumonitis that required corticosteroids, has current ILD\u002Fpneumonitis, or where suspected ILD\u002Fpneumonitis cannot be ruled out by imaging at screening.\n\n11\\. Uncontrolled or significant cardiovascular disease, including the following:\n\n1. QT interval corrected with Fridericia's formula interval \\>470 ms (average of triplicate determinations).\n2. Diagnosed or suspected long QT syndrome or known family history of long QT syndrome.\n3. History of clinically relevant ventricular arrhythmias, such as ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes.\n4. Myocardial infarction within 6 months prior to screening.\n5. Uncontrolled angina pectoris within 6 months prior to screening.\n6. New York Heart Association Class 2 to 4 congestive heart failure.\n7. Patients with uncontrolled hypertension (defined as systolic blood pressure ≥ 160 mmHg and\u002For diastolic blood pressure ≥100 mmHg) based on an average of ≥ 3 BP readings on ≥ 2 sessions.\n8. Complete left or right bundle branch block.\n9. Patients with troponin levels above ULN at screening (as defined by the manufaccturer), and wit any MI related symptoms. (For patients with elevated troponin levels but no MI symptoms, a cardiology consultation during the screening period is recommended..\n\n   12\\. Patient is currently participating and receiving study treatment or has participated in a study of an investigational agent and received study treatment or used an investigational device within 4 weeks of the first dose of treatment.\n\n   13\\. Patients with evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation) 14. Patients with current abdominal\u002F pelvic fistula. 15. Patient is considered a poor medical condition due to a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active infection requiring systemic therapy. Specific examples include, but are not limited to, active, non-infectious pneumonitis; uncontrolled ventricular arrhythmia; uncontrolled major seizure disorder; unstable spinal cord compression; superior vena cava syndrome; or any psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study(including obtaining informed consent).\n\n   16\\. Prior exposure to other HER2-targeted agents or antibody-drug conjugate that consists of an exatecan derivative that is a topoisomerase I inhibitor 17. Patient is pregnant or breastfeeding or is expecting to conceive children within the projected duration of the study, starting with the screening visit through 7 months after the last dose of study treatment, or lactating woman.\n\n   18\\. Live vaccines within 30 days of first dose of study intervention and while receiving study intervention. Administration of inactivated vaccines (i.e. inactivated influenza vaccine) is permitted. Inactivated RNA or nonreplicating viral vector-based SARS-CoV-2 vaccines are allowed, as approved by local\u002Fregional Health Authorities. Novel live attenuated SARS-CoV-2 vaccines are not permitted.","FEMALE","18 Years",{"count":20,"type":21},116,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Ovarian, fallopian tube, and peritoneal cancers are often diagnosed at an advanced stage, requiring chemotherapy. Recently, the standard treatment, platinum-based chemotherapy plus PARP inhibitors, has extended disease-free survival (PFS). However, most patients eventually develop resistance to PARP inhibitors and become unresponsive to conventional treatments. Therefore, an effective standard treatment for patients who relapse after PARP inhibitor resistance has not yet been established. Meanwhile, HER2 protein expression has been identified in some patients, drawing attention as a new therapeutic target.\n\nTrastuzumab deruxtecan (T-DXd), an antibody-drug conjugate (ADC) targeting HER2, has already demonstrated efficacy and safety in other HER2-positive cancers. This study aimed to explore the potential of T-DXd as a new treatment option by evaluating the efficacy and safety of T-DXd in patients with ovarian, fallopian tube, and peritoneal cancer who relapsed after PARP inhibitor treatment and who express HER2.\n\nParticipants will:\n\n* Arm A: T-DXd +\u002F- Bevacizumab, IV, every 3weeks\n* Arm B: Platinum-based chemotherapy +\u002F- Bevacizumab, IV",[27,28,29,30],"Ovarian Cancer","Ovarian Carcinoma, Recurrent","Ovarian Cancer Metastatic Recurrent","Ovarian Cancer (OvCa)",[15,32,33],"APGOT-OV14","ENGOT-ov92","RECRUITING","2026-04-17",{"date":37,"type":38},"2026-04-20","ACTUAL",{"date":40,"type":38},"2026-02-26",{"date":42,"type":21},"2030-12-31",{"name":44,"class":45},"Yonsei University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":66,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":94},"100627144","phase-1-study-evaluating-the-safety-and-efficacy-of-hwk-007-a-ptk7-directed-antibody-drug-conjugate-in-participants-with-advanced-solid-tumors-100627144","NCT07444814","Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors","A Phase 1 First-in-Human Study of PTK7-Directed Antibody Drug Conjugate HWK-007 in Participants With Advanced Solid Tumors","Inclusion Criteria:\n\nHave one of the following solid tumor cancers:\n\n1. Monotherapy escalation and backfill cohorts:\n\n   1. non-squamous EGFR-Wt NSCLC\n   2. Endometrial carcinoma\n   3. Platinum Resistant Ovarian Cancer\n2. Monotherapy expansion cohorts:\n\n   1. Non-squamous EGFR-Wt NSCLC\n   2. Additional tumor indications to be defined in a future amendment\n\nExclusion Criteria:\n\n1. Individual with known or suspected uncontrolled central nervous system (CNS) metastases\n2. Individual with history of carcinomatous meningitis\n3. Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection\n4. Individual with evidence of corneal keratopathy or history of cornea transplant\n5. Any serious unresolved toxicities from prior therapy\n6. Significant cardiovascular disease\n7. Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 milliseconds (ms)\n8. History of pneumonitis\u002Finterstitial lung disease\n9. Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention","ALL",{"count":56,"type":21},226,[58],"PHASE1","HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid tumors known to be expressing PTK7. The study employs a sequential dose escalation and dose expansion design without a control group.",[61,27,62,29,63,64,65],"Endometrial Cancer","Ovarian Cancer Metastatic","Non-squamous EGFR Wt NSCLC","Platinum Resistant Ovarian Cancer","PROC",[67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,64,83],"PTK7","Ovarian cancer","Endometrial cancer","NSCLC","Lung cancer","Chemotherapy","ADC","Antibody-Drug-Conjugate","Solid tumor","Phase 1","Ovarian neoplasms","Endometrial neoplasms","Carcinoma, Non Small Cell Lung","Lung neoplasms","Gynecologic cancer","EGFR Wt NSCLC","DNA Topoisomerase I","2026-03-26",{"date":86,"type":38},"2026-03-27",{"date":88,"type":38},"2025-12-19",{"date":90,"type":21},"2028-12",{"name":92,"class":93},"Whitehawk Therapeutics, Inc.","INDUSTRY",12,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":104,"briefSummary":105,"conditions":106,"keywords":107,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":120},"100616897","phase-2-disitamab-vedotin-combined-with-platinum-and-bevacizumab-as-first-line-and-maintenance-therapy-for-her2-expressing-hrd-negative-high-risk-ovarian-cancer-a-multicenter-non-randomized-single-arm-phase-ii-clinical-study-100616897","NCT07311577","Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study","Inclusion Criteria:\n\n* Voluntary participation with written informed consent.\n* Age 18-75 years.\n* Expected survival ≥ 12 weeks.\n* Histologically\u002Fcytologically confirmed advanced ovarian carcinoma (FIGO Stage III-IV).\n* HRD-negative status per local assessment.\n* High-risk features: macroscopic residual disease after primary cytoreductive surgery for Stage III; prior neoadjuvant chemotherapy; or Stage IV disease.\n* ≥ 1 RECIST v1.1 measurable lesion (long-axis ≥ 10 mm by spiral CT or ≥ 15 mm short-axis for lymph nodes).\n* HER2 expression documented locally (IHC 1+, 2+, or 3+); archival or fresh tumor tissue (paraffin block or unstained slides) must be available for central confirmation.\n* ECOG performance status 0-1.\n* Adequate organ function within 14 days before enrolment (no transfusion\u002Fhaematinics\u002FG-CSF allowed):\n\nHaematology\n\n1. Hb ≥ 90 g\u002FL\n2. WBC ≥ 3 × 10⁹\u002FL\n3. ANC ≥ 1.5 × 10⁹\u002FL\n4. PLT ≥ 90 × 10⁹\u002FL Biochemistry\n\na) TBIL ≤ 1.5 × ULN b) ALT\u002FAST\u002FALP ≤ 3 × ULN (≤ 5 × ULN if liver metastases) c) Serum creatinine ≤ 1.5 × ULN or CrCl ≥ 60 mL\u002Fmin (Cockcroft-Gault)\n\n* Urinalysis: dipstick proteinuria \\\u003C 2+ or 24-h urine protein \\\u003C 1 g.\n* Cardiac function: NYHA class \\\u003C III and LVEF ≥ 50 % by echocardiography. -\n* Women must be surgically sterile, post-menopausal, or use an approved contraceptive method from screening until 6 months after the last dose; serum pregnancy test negative within 7 days of first dose and not breastfeeding.\n* Able and willing to comply with all study and follow-up procedures.\n\nExclusion Criteria:\n\n* Non-high-risk histologic sub-types of ovarian carcinoma.\n* CNS metastases and\u002For carcinomatous meningitis. -\n* Requirement for parenteral hydration\u002Fnutrition OR clinical\u002Fradiologic evidence of partial bowel obstruction or perforation.\n* ≥ Grade-2 peripheral neuropathy. -\n* Active bleeding or high bleeding-risk conditions (e.g., known coagulopathy, tumour encasing major vessels).\n* Interval between cytoreductive surgery and first bevacizumab dose \\\u003C 28 days.\n* Concurrent malignancy or history of another primary malignancy within 5 years (except adequately treated in-situ cervix cancer, basal- or squamous-cell skin cancer).\n* Major surgery within 4 weeks before first study dose and not fully recovered.\n* Symptomatic or medically-requiring large-volume pleural effusion or ascites. - Live-attenuated vaccine within 30 days before first dose or planned during study.\n* Significant arterial\u002Fvenous thrombo-embolic or cerebro-cardiovascular event within 12 months before screening (e.g., DVT, PE, cerebral infarction, intracranial haemorrhage, MI); asymptomatic calf-muscle DVT not needing intervention or lacunar infarct without sequelae are allowed.\n* Uncontrolled systemic diseases judged by investigator: diabetes, liver cirrhosis Child-Pugh B\u002FC, interstitial pneumonitis, severe COPD, etc.\n* Clinically-relevant cardiovascular disorders:\n\n  1. PR interval \\> 0.24 s or 2nd\u002F3rd-degree AV block.\n  2. Uncontrolled hypertension (SBP \\> 150 mmHg or DBP \\> 90 mmHg).\n  3. MI, unstable angina or significant arrhythmia \\\u003C 6 months before enrolment.\n  4. NYHA class ≥ II congestive heart failure.\n  5. Serious arrhythmia requiring anti-arrhythmic therapy.\n  6. ≥ Stage-II peripheral vascular disease (except transient ischaemia \\\u003C 24 h without permanent deficit and no surgery).\n  7. Cerebrovascular accident within 6 months.\n* Severe infection within 4 weeks before first dose (IV antibiotics\u002Fantifungals\u002F antivirals required) or unexplained fever \\> 38.5 °C during screening; major surgery within 3 weeks.\n* Active autoimmune or immunodeficiency disorders (e.g., autoimmune hepatitis, interstitial pneumonia, uveitis, RA, IBD, hypophysitis, vasculitis, nephritis). Exceptions: stable hypothyroidism on replacement, type-1 diabetes well controlled with insulin.\n* Autoimmune disease requiring systemic immunosuppressive\u002Fimmunomodulatory therapy within 2 years before first dose (stable replacement therapy with thyroxine, insulin or physiological corticosteroids permitted).\n* Active or poorly controlled infection, including:\n\n  1. HIV positive (HIV-1\u002F2 antibody).\n  2. Active hepatitis B (HBsAg positive or HBV DNA \\> 2 000 IU\u002FmL with abnormal LFT).\n  3. Active hepatitis C (HCV antibody positive or HCV RNA ≥ 10³ copies\u002FmL with abnormal LFT).\n  4. Active tuberculosis.\n  5. Other uncontrolled infection \\> CTCAE v5.0 grade 2.\n* History of other malignancy within 5 years (except adequately treated in-situ cervical cancer or basal\u002Fsquamous-cell skin cancer). -\n* Concurrent participation in another interventional clinical trial or investigational agent\u002Fdevice within 4 weeks before first dose. -\n* Known hypersensitivity or intolerance to study drugs or their excipients. -\n* History of substance abuse that cannot be abstained from, or any psychiatric disorder that may interfere with compliance.\n\nAny other condition that, in the investigator's opinion, could increase risk or preclude safe completion of the protocol.","75 Years",{"count":103,"type":21},43,[24],"This is a prospective, multicenter, phase II study designed to evaluate the efficacy and safety of disitamab vedotin combined with platinum plus bevacizumab as first-line therapy for HER2-expressing, HRD-negative high-risk ovarian cancer. Forty-three patients with pathologically confirmed HRD-negative high-risk ovarian cancer will be enrolled. After enrollment, patients will receive disitamab vedotin plus platinum and bevacizumab as first-line and maintenance treatment.\n\nFirst-line phase:\n\nCarboplatin AUC 5 intravenously on Day 1 every 21 days over 1 h ,Bevacizumab 7.5-15 mg\u002Fkg intravenously on Day 1 every 21 days over 30-90 min.\n\nMaintenance phase:\n\nPatients who achieve response (CR or PR) will continue disitamab vedotin monotherapy plus bevacizumab (investigator decides whether to continue disitamab vedotin and for how long).\n\nMaintenance duration: bevacizumab until disease progression or up to 22 cycles; disitamab vedotin up to 6 months (8 cycles).",[62,29],[108,109,110],"RC48","HRD-Negative High-Risk Ovarian Cancer","HER2-expressing","2025-12-29",{"date":113,"type":38},"2025-12-31",{"date":115,"type":21},"2026-01-01",{"date":117,"type":21},"2028-12-30",{"name":119,"class":45},"Jiangsu Cancer Institute & Hospital",2,{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":129,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":134,"conditions":135,"keywords":136,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":120},"100580580","phase-2-inhibiting-beta-adrenergic-and-cox-2-signaling-during-the-perioperative-period-to-reduce-ovarian-cancer-progression-100580580","NCT06839144","Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression","Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression: A Randomized Placebo-Controlled Clinical Trial","OC-POP-PT","Inclusion Criteria:\n\n* Age 20-85\n* ASA score 1-3 or ECOG Performance Status of 0 to 2\n* Patients with a suspected high-grade ovarian epithelial cancer based on imaging, clinical examination, CA125, and\u002For tumor biopsy\n* Patients planned for surgery for primary surgery, or interval debulking surgery for ovarian cancer\n* Signed informed consent form\n* Willing and able to comply with study procedures (physically and mentally)\n\nExclusion Criteria:\n\n* Patients who participate in another interventional study\n* Patients with known allergy to one or more of the study medications, or to any medication from the non-steroidal anti-inflammatory drug group or beta-blockers family\n* Patients treated chronically with any type of a beta-adrenergic blocker or a COX inhibitor, except use of Aspirin, which will be discontinued at least 7 days prior to surgery, and until 3 weeks post-surgery\n* Patients currently suffering from asthma (אסתמה פעילה בלבד), or required hospital admission or change in medical treatment for asthma within the past year\n* Patients with active peptic disease\n* Patients with a history of CVA\u002FTIA\n* Recent (within the last 5 years) or concurrent malignancies, with the exception of adequately treated in-situ carcinoma of the cervix or basal-cell carcinoma of the skin\n* Patients with renal failure, measured by creatinine level \\>1.5\n* Patients with significant liver dysfunction (known cirrhosis, Bilirubin level\\>2)\n* Patients with significant heart failure (NYHA functional class 3 or Higher)\n* Patients with bradycardia (heart rate of 50 or less) or second- or third-degree AV block\n* Patients with right-sided heart failure owing to pulmonary hypertension\n* Patients with chronic Digoxin treatment\n* Patients with Printzmetal's angina\n* Patients with significant diagnosed cardiomegaly\n* Patients suffering from sick sinus syndrome\n* Patients with peripheral vascular disease\n* Patients with current (unresected) pheochromocytoma\n* Pregnant women\n* Patients who are treated with immunosuppressive medications, including chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial drug\n* Patients with Immunodeficiency Disorders","20 Years","85 Years",{"count":132,"type":21},60,[24],"This study investigates the impact of perioperative inhibition of beta-adrenergic and COX-2 signaling in ovarian cancer patients undergoing debulking surgery. The trial aims to assess the feasibility, safety, and biological effects of a combination of propranolol and etodolac in reducing cancer metastasis and improving immune responses.",[27,29],[27,137,138,139,140,141,142,143,144,145],"Perioperative Intervention","Beta-Blockers","Propranolol","COX-2 Inhibitors","Etodolac","Psychoneuroimmunology","Stress and Cancer","Randomized Controlled Trial (RCT)","Biomarker Analysis","2025-07-08",{"date":148,"type":38},"2025-07-11",{"date":150,"type":38},"2025-03-12",{"date":152,"type":21},"2026-08-31",{"name":154,"class":155},"Tel-Aviv Sourasky Medical Center","OTHER_GOV"]